Thenzing J. Silva-Hurtado
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thenzing J. Silva-Hurtado has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Raymund L. Yong
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, New York
40 shared publications - Balagopal Pai
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
39 shared publications - Elena Zaslavsky
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
39 shared publications - Kristin G. Beaumont
Icahn School of Medicine at Mount Sinai
39 shared publications - Susana Isabel Ramos
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
39 shared publications - Emine Özen
Department of Biomedical Engineering, Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University in the City of New York, New York, New York
38 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 28 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Expanding the molecular grading criteria in IDH-mutant astrocytoma
Background: IDH-mutant astrocytomas are classified as WHO grade 4 in the presence of conventional high-grade histologic features and/or homozygous CDKN2A/B deletion in the 5th edition of the WHO Classification of Central Nervous System Tumour guidelines. However, work over the past decade has indicated a number of other molecular alterations that warrant consideration as potential prognostic markers. Methods: We used univariate Kaplan-Meier and multivariate Cox proportional hazards regression analysis to evaluate the prognostic effects of homozygous CDKN2A/B deletion, CDK4 amplification, CCND2 amplification, PDGFRA amplification/mutation, PIK3R1 mutation, PIK3CA mutation, MYCN amplification, EGFR amplification/mutation, TERT promoter mutation, and grade 4 histologic features in two independent cohorts of WHO grade 2-4 IDH-mutant astrocytoma (n = 840 and n = 367). Results: The presence of CDK4 amplification, CCND2 amplification, PDGFRA alteration, PIK3R1 mutation, MYCN amplification, and EGFR alteration were each associated with reduced overall survival compared to WHO grade 2/3 astrocytomas without these molecular features. 17.7% (148/837) of otherwise grade 2/3 astrocytomas had one or more of these molecular criteria, with resulting intermediate clinical outcome in terms of overall survival (median survival of 67.3-82.0 months) compared to grade 2/3 astrocytomas without these molecular features (median survival of 135.0-140.7 months) and grade 4 astrocytomas (median survival of 35.3-45.0 months). Conclusions: The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
- 28 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Top Cited PapersOpen AccessExpanding the molecular grading criteria in IDH-mutant astrocytoma
Background: IDH-mutant astrocytomas are classified as WHO grade 4 in the presence of conventional high-grade histologic features and/or homozygous CDKN2A/B deletion in the 5th edition of the WHO Classification of Central Nervous System Tumour guidelines. However, work over the past decade has indicated a number of other molecular alterations that warrant consideration as potential prognostic markers. Methods: We used univariate Kaplan-Meier and multivariate Cox proportional hazards regression analysis to evaluate the prognostic effects of homozygous CDKN2A/B deletion, CDK4 amplification, CCND2 amplification, PDGFRA amplification/mutation, PIK3R1 mutation, PIK3CA mutation, MYCN amplification, EGFR amplification/mutation, TERT promoter mutation, and grade 4 histologic features in two independent cohorts of WHO grade 2-4 IDH-mutant astrocytoma (n = 840 and n = 367). Results: The presence of CDK4 amplification, CCND2 amplification, PDGFRA alteration, PIK3R1 mutation, MYCN amplification, and EGFR alteration were each associated with reduced overall survival compared to WHO grade 2/3 astrocytomas without these molecular features. 17.7% (148/837) of otherwise grade 2/3 astrocytomas had one or more of these molecular criteria, with resulting intermediate clinical outcome in terms of overall survival (median survival of 67.3-82.0 months) compared to grade 2/3 astrocytomas without these molecular features (median survival of 135.0-140.7 months) and grade 4 astrocytomas (median survival of 35.3-45.0 months). Conclusions: The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Extended Data 17 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
List of pseudotime module genes for ST2 core-to-margin trajectory analysis
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data 17 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
List of pseudotime module genes for ST2 core-to-margin trajectory analysis
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Extended Data 20 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of differential peak accessibility analysis tumor, Core vs. Margin
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data 20 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of differential peak accessibility analysis tumor, Core vs. Margin
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Extended Data 4 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of entire Hallmark enrichment analysis
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data 4 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of entire Hallmark enrichment analysis
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Extended Data 22 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table summary of TEAD1 ChiP-seq differential gene-peak analysis, GBM vs. control
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data 22 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table summary of TEAD1 ChiP-seq differential gene-peak analysis, GBM vs. control
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Extended Data 19 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of differential motif enrichment analysis in all cell types, Core vs. Margin
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessExtended Data 19 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Table of differential motif enrichment analysis in all cell types, Core vs. Margin
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Summary of omics studies on infiltrative glioma biology
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Summary of omics studies on infiltrative glioma biology
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Despite genomic heterogeneity, most high-grade gliomas (HGG), including IDH wild-type glioblastoma, display diffusely infiltrative growth, which impedes complete surgical resection and leads to inevitable recurrence. Understanding of HGG biology comes predominantly from studies using resected “core” tissue. Paradoxically, chemoradiation targets residual disease at the resection margin, which remains poorly defined. To address this, we generated a high-throughput single-nucleus RNA sequencing (snRNA-seq) and single-nucleus assay for transposase-accessible chromatin using sequencing (snATAC-seq) multiomic dataset from matching “core” and “margin” dissections in four distinct grade 4 HGG (36,811 snRNA-seq and 30,705 snATAC-seq nuclei after filtering from EGFR amplified, NF1 mutant, FGFR3–TACC3 fused, and IDH1 mutant HGG) and combined it with new spatial transcriptomics data from two additional HGG (EGFR amplified and CDK4 amplifed) to evaluate “core-to-margin” transition. Computational analyses included functional enrichment, comparison with prior HGG datasets, differential analyses in core versus margin cell types or regions of interest for genes, chromatin accessibility peaks, cell–cell interactions, transcription factor motif activity and associated regulon targets, and reconstruction of core-to-margin transition using RNA velocity and pseudotime. Contrasting tumor-specific biology in matching core and margin dissections defined a unique, shared “glioma infiltration” signature near the margin. EGFR was prioritized as a top differentially expressed and accessible tumor margin marker across HGG subtypes that showed dynamic expression along a core-to-margin infiltration trajectory. CRISPR/Cas9-mediated deletion of EGFR in two patient-derived models validated its role in migration, and combined snATAC-seq with chromatin immunoprecipitation sequencing studies suggested a role for TEAD1 as a transcriptional regulator of EGFR at the margin. This multiomic resource will enable further studies into residual disease biology of tumors and the microenvironment at the infiltrative margin.Significance:Characterization of infiltrating tumor-margin cells across human high-grade gliomas advances the understanding of residual disease biology at the surgical margin, identifies mechanisms of therapy resistance and recurrence, and elucidates targetable molecular features.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Multiomics Defines a Shared Tumor Infiltrative Signature at the Resection Margin in High-Grade Gliomas
Despite genomic heterogeneity, most high-grade gliomas (HGG), including IDH wild-type glioblastoma, display diffusely infiltrative growth, which impedes complete surgical resection and leads to inevitable recurrence. Understanding of HGG biology comes predominantly from studies using resected “core” tissue. Paradoxically, chemoradiation targets residual disease at the resection margin, which remains poorly defined. To address this, we generated a high-throughput single-nucleus RNA sequencing (snRNA-seq) and single-nucleus assay for transposase-accessible chromatin using sequencing (snATAC-seq) multiomic dataset from matching “core” and “margin” dissections in four distinct grade 4 HGG (36,811 snRNA-seq and 30,705 snATAC-seq nuclei after filtering from EGFR amplified, NF1 mutant, FGFR3–TACC3 fused, and IDH1 mutant HGG) and combined it with new spatial transcriptomics data from two additional HGG (EGFR amplified and CDK4 amplifed) to evaluate “core-to-margin” transition. Computational analyses included functional enrichment, comparison with prior HGG datasets, differential analyses in core versus margin cell types or regions of interest for genes, chromatin accessibility peaks, cell–cell interactions, transcription factor motif activity and associated regulon targets, and reconstruction of core-to-margin transition using RNA velocity and pseudotime. Contrasting tumor-specific biology in matching core and margin dissections defined a unique, shared “glioma infiltration” signature near the margin. EGFR was prioritized as a top differentially expressed and accessible tumor margin marker across HGG subtypes that showed dynamic expression along a core-to-margin infiltration trajectory. CRISPR/Cas9-mediated deletion of EGFR in two patient-derived models validated its role in migration, and combined snATAC-seq with chromatin immunoprecipitation sequencing studies suggested a role for TEAD1 as a transcriptional regulator of EGFR at the margin. This multiomic resource will enable further studies into residual disease biology of tumors and the microenvironment at the infiltrative margin.Significance:Characterization of infiltrating tumor-margin cells across human high-grade gliomas advances the understanding of residual disease biology at the surgical margin, identifies mechanisms of therapy resistance and recurrence, and elucidates targetable molecular features.